DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Temozolomide - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Antineoplastic Agents

Dosage Forms

  • Capsule

Brands / Synonyms

Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida [Spanish]; Temozolomide [Ban:Inn]; Temozolomidum [Latin]


For the treatment of adult patients diagnosed with anaplastic astrocytoma who have relapsed following chemotherapy


Temozolomide is an antineoplastic agent. It causes death of of rapidly replicating cells, especially malignant cells, leading to regression or slowed tumor growth.

Mechanism of Action

Temozolomide is not active until it is converted at physiologic pH to the active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is due to alkylation of DNA at the O6 and N7 positions of guanine.


Rapid and complete absorption in the gastrointestinal tract


Not Available

Biotrnasformation / Drug Metabolism

Not Available


TEMODAR (temozolomide) Capsules are contraindicated in patients who have a history of hypersensitivity reaction to any of its components. TEMODAR is also contraindicated in patients who have a history of hypersensitivity to DTIC, since both drugs are metabolized to MTIC.

Drug Interactions

Administration of valproic acid decreases oral clearance of temozolomide by about 5%. The clinical implication of this effect is not known.

Patients with Severe Hepatic or Renal Impairment

Caution should be exercised when TEMODAR Capsules are administered to patients with severe hepatic or renal impairment.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017